This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Bio-Techne Corp (TECH)

NASDAQ: Health Care

$91.41 +1.01 | 1.12%
11/25/15 - 4:00:00 PM ET
  • Prev Close: 90.40
  • Day's Open: 90.56
  • Volume: 174.39K
  • Avg Vol: 232.70K
  • Shares Outstanding: 37.19M
  • Mkt Cap: 3.40B
  • Div: $0.32
  • Div Yield: 1.40%
  • P/E: 31.82
  • EPS: 2.90
TECH Day's Range
TECH 52 Week Range
TECH Business Summary
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic products worldwide. The company operates through three segments: Biotechnology, Clinical Controls, and Protein Platforms.View TECH key stats
Bio-Techne Corp - TECH - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Bio-Techne Corp as a Buy with a ratings score of B.
Report Snippet: We rate BIO-TECHNE CORP (TECH) a BUY. This is driven by some important positives, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity.
Rating: 3.67 out of 5, 'B' Buy.
You can view the full analysis from the report here:
TECH Rating Report
TECH Performance as of Prev. Close
TECH EPS Performance
1-Yr Ago
2-Yrs Ago
3-Yrs Ago
TECH Percentage in these ETFs

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

TECH Bio-Techne Corp

Chart of TECH

Analysts Ratings for TECH

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 4 4 4
Moderate Buy 0 0 0 0
Hold 2 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0

TECH Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs